People: Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

14 Oct 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Schenkein, David 

Dr. David P. Schenkein, M.D., has been appointed Executive Chairman of the Board of the Company. Dr. Schenkein has served as a member of our board of directors since August 2009 and as our executive chairman since February 2019. Dr. Schenkein also served as our president and chief executive officer from August 20019 until February 2019. Dr. Schenkein has been a hematologist and medical oncologist for more than 20 years. He currently serves as a general partner of GV, the venture capital arm of Alphabet Inc. (formerly Google), and is an adjunct attending physician in hematology at Tufts Medical Center. Prior to joining Agios, from 2006 to 2009, Dr. Schenkein was the senior vice president, clinical hematology/oncology at Genentech, Inc., a pharmaceutical company (now a member of the Roche Group, a global healthcare company), or Genentech, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for its bio-oncology portfolio. While at Genentech, he served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the senior vice president of clinical research at Millennium Pharamaceutials, Inc., a biopharmaceutical company (now Takeda Oncology), or Millennium, overseeing the clinical development and worldwide approval of VELCADE®, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. Dr. Schenkein currently serves on the board of directors of bluebird bio, Inc. and Denali Therapeutics Inc., both public biotechnology companies, and was formerly on the board of Foundation Medicine, Inc., a public biotechnology company. Dr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.

Basic Compensation

Total Annual Compensation, USD 625,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 7,574,320
Fiscal Year Total, USD 8,199,320

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 366,849 29,813,200.00